NEW YORK (GenomeWeb News) – Allele Biotech on Friday announced that it has signed a contract with the National Cancer Institute to conduct RNAi screening aimed at identifying synthetic targets for killing cancer cells.
The San Diego-based firm will use its high-quality fluorescent proteins, lentivirus systems, and shRNA platform for the project. It noted that the University of Florida is a sub-contractor on the contract.
Allele said that the goal of the project is to eventually screen all DNA repair genes in all possible combinations in multiple cancer cells to find the best combination cancer treatment strategy.
Financial and other terms of the agreement were not disclosed.